Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Varsha Gandhi, PhD, on Ibrutinib

Dec

Today In Oncology

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Varsha Gandhi, PhD, on Ibrutinib

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL